Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $34

Truist Securities analyst Gregory Renza has maintained a Buy rating on Zymeworks (NASDAQ: ZYME) and increased the price target from $32 to $34. This adjustment reflects a positive outlook for the company's stock performance.